Multi-drug-resistant tuberculosis future or investigational therapies

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [2]

Since new drug resistant tuberculosis have been emerging, the role of future therapies is vital in curbing outbreaks. The new drugs should be more effective than the current regimen and a few drugs in clinical trials have been showing good results.

Any future regimen should satisfy the following principles. ^[1]

• It should not have more than a maximum duration of 6 months
• The dosing schedule must be simple
• The number of drugs in it should be ideally not more than 3-5 drug each from a different class
• It should have minimum side effect profile so that we could have minimum monitoring
• It should be effective against MDR, XDR and XXDR strains
• It should be administered per orally
• It should have minimum interaction with anti retroviral drugs.
• It should have atleast one new class of drug

Template:WH Template:WS